Prisman Händedesinfektion Disinfectant Authorized in the EU: What Manufacturers and Distributors Must Do

Key data

Manufacturers and distributors of hand disinfectants operating with the Prisman Händedesinfektion biocide family can now market their products in any EU Member State under a single European authorization. The Commission Implementing Regulation (EU) 2026/1410, in force since 26 June 2026, eliminates the need to obtain national authorizations country by country, simplifying access to the single market.

However, this authorization is not unconditional. The regulation establishes specific requirements for labeling, composition and use restrictions that must be met in all marketed batches. For the healthcare, hospitality and services sector that already uses these products, the immediate obligation is to verify that available batches comply with the new conditions.

What does this regulation establish?

Commission Implementing Regulation (EU) 2026/1410 grants a Union authorization for the Prisman Händedesinfektion biocide family, under the Regulation (EU) No 528/2012 on the marketing and use of biocidal products.

The key points of what it establishes are:

• Single European authorization: the product can be marketed and used in all Member States without the need for additional national authorizations.
• Labeling conditions: manufacturers must strictly comply with the labeling requirements set out in the authorization.
• Composition conditions: the product formulation must conform to the authorized composition; any variation may invalidate the authorization.
• Use restrictions: the regulation establishes specific limitations on how and in what contexts the product may be used.
• Consequences of non-compliance: failure to comply with any of these conditions may result in market withdrawal and administrative sanctions.

Union authorization is the mechanism provided for in Regulation (EU) 528/2012 for biocidal products with potential market in several Member States. It replaces the model of individual national authorizations with a single title valid throughout the EU, managed at European level.

Economic and operational impact

For manufacturers, single authorization represents a significant reduction in administrative burden: it is no longer necessary to obtain and maintain authorizations in each country where you want to sell. This reduces regulatory management costs and accelerates time to market entry in new Member States.

For distributors, the most immediate impact is operational: they must verify that batches in stock and new orders comply with the labeling and composition conditions established in the regulation. A batch that does not comply may be subject to market withdrawal, with the economic and reputational cost that entails.

For professional users (hospitals, clinics, hotels, restaurants, cleaning companies), the obligation is to verify that the products they purchase are covered by the new authorization and that their use complies with the established restrictions. Using a biocidal product outside authorized conditions may generate administrative liability.

The main economic risk identified in the regulation is the market withdrawal of non-compliant batches, which may result in inventory losses, return costs and possible administrative sanctions whose specific amount is not specified in the implementing regulation.

Who does it affect?

• Manufacturers of the Prisman Händedesinfektion biocide family that market in the EU.
• Distributors wholesale and retail of biocidal hand disinfectants in any Member State.
• Healthcare sector: hospitals, clinics, health centers, nursing homes and any facility that uses hand disinfectants professionally.
• Hospitality sector: hotels, restaurants, bars and collective catering establishments.
• Service companies: cleaning companies, facilities management and professional hygiene services.
• Procurement and quality managers in any organization that regularly purchases these products.

Practical example

A Spanish hotel chain operating in Spain, France and Portugal uses the Prisman Händedesinfektion family in its facilities. Until now, the supplier had to have national authorizations in each of the three countries to legally supply the product.

With the entry into force of Regulation (EU) 2026/1410, the supplier has a single European authorization valid in all three countries. The hotel chain, for its part, must verify that the batches it receives from 26 June 2026 onwards comply with the labeling and composition conditions established in the new authorization. If it detects batches with non-compliant labeling, it must communicate this to the supplier and suspend their use until the situation is regularized, to avoid administrative liability.

What should companies do now?

1. Verify the status of batches in stock: check that Prisman Händedesinfektion products available in warehouse comply with the labeling and composition conditions established in Regulation (EU) 2026/1410.
2. Request documentation from the supplier: request written confirmation that the supplied batches are covered by the new Union authorization and are compliant with its conditions.
3. Review use procedures: ensure that the use of the product in facilities complies with the use restrictions established in the authorization, especially in healthcare and food service environments.
4. Update internal documentation: incorporate the reference to Regulation (EU) 2026/1410 in the records of biocidal products used, safety data sheets and hygiene procedures.
5. Establish an alert protocol: define what to do if a non-compliant batch is detected (suspension of use, communication to the supplier, notification to the competent authority if applicable) to avoid administrative sanctions and market withdrawals.

Official source

Consult complete regulation in official source

Disclaimer: This article is for informational purposes only and does not constitute legal advice. For specific decisions, consult a qualified professional. Source: https://eur-lex.europa.eu/./legal-content/AUTO/?uri=OJ:L_202601410